MX2018001566A - Construcciones de union a antigeno para moleculas diana. - Google Patents

Construcciones de union a antigeno para moleculas diana.

Info

Publication number
MX2018001566A
MX2018001566A MX2018001566A MX2018001566A MX2018001566A MX 2018001566 A MX2018001566 A MX 2018001566A MX 2018001566 A MX2018001566 A MX 2018001566A MX 2018001566 A MX2018001566 A MX 2018001566A MX 2018001566 A MX2018001566 A MX 2018001566A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding constructs
target molecules
bind
constructs
Prior art date
Application number
MX2018001566A
Other languages
English (en)
Spanish (es)
Inventor
Gudas Jean
Kadyl Satpayev Daulet
Yuri Torgov Michael
Mui Chan Chio
Olafsen Tove
Original Assignee
Imaginab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imaginab Inc filed Critical Imaginab Inc
Publication of MX2018001566A publication Critical patent/MX2018001566A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2018001566A 2015-08-07 2016-08-04 Construcciones de union a antigeno para moleculas diana. MX2018001566A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562202665P 2015-08-07 2015-08-07
PCT/US2016/045580 WO2017027325A1 (en) 2015-08-07 2016-08-04 Antigen binding constructs to target molecules

Publications (1)

Publication Number Publication Date
MX2018001566A true MX2018001566A (es) 2019-04-25

Family

ID=57984170

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001566A MX2018001566A (es) 2015-08-07 2016-08-04 Construcciones de union a antigeno para moleculas diana.
MX2022014463A MX2022014463A (es) 2015-08-07 2018-02-06 Construcciones de union a antigeno para moleculas diana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014463A MX2022014463A (es) 2015-08-07 2018-02-06 Construcciones de union a antigeno para moleculas diana.

Country Status (14)

Country Link
US (2) US11254744B2 (https=)
EP (2) EP3331564B1 (https=)
JP (4) JP7026613B2 (https=)
KR (2) KR102749049B1 (https=)
CN (2) CN115960230A (https=)
AU (3) AU2016304764C1 (https=)
CA (1) CA2994951A1 (https=)
ES (1) ES3020458T3 (https=)
MX (2) MX2018001566A (https=)
NZ (1) NZ739721A (https=)
RU (1) RU2765242C2 (https=)
SG (1) SG10201913625XA (https=)
WO (1) WO2017027325A1 (https=)
ZA (1) ZA201801391B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
EP3359574B1 (en) 2015-10-06 2020-04-22 City of Hope Chimeric antigen receptors targeted to psca
EP3432924A1 (en) * 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
WO2018047154A1 (en) 2016-09-07 2018-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-nkp46 antibodies and therapeutic use of same
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
KR102367658B1 (ko) * 2017-03-29 2022-02-25 타이페이 메디컬 유니이버시티 항원 특이적 t 세포 및 그의 용도
CN106831995A (zh) * 2017-03-31 2017-06-13 北京百特美博生物科技有限公司 新型双特异性抗体及其用途
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
CA3089167A1 (en) * 2018-02-09 2019-08-15 National University Of Singapore Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
CN109161532A (zh) * 2018-05-31 2019-01-08 华东师范大学 同时靶向psma和pd-l1的工程化免疫细胞
WO2019236684A1 (en) 2018-06-08 2019-12-12 Imaginab, Inc. Antigen binding constructs to cd4
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
EP3994177A4 (en) * 2019-07-02 2023-09-20 Telix International Pty Ltd PSMA-BINDING ANTIBODIES WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR
CN115103633B (zh) * 2019-12-05 2023-09-12 伊麦吉纳博公司 使用多种成像剂的成像方法
US20230390424A1 (en) * 2020-09-11 2023-12-07 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
JP2023548553A (ja) * 2020-11-03 2023-11-17 ザ ジェネラル ホスピタル コーポレイション 治療用放射性標識ナノ粒子およびその使用方法
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
IL309767A (en) * 2021-07-13 2024-02-01 Generation Bio Co Single chain variable fragment (scfv) modified lipid nanoparticle compositions and uses thereof
KR20240069748A (ko) * 2021-09-16 2024-05-20 지티 바이오파마, 인크. B7-h3 표적화 융합 단백질 및 그의 사용 방법
CN115724978A (zh) * 2022-08-17 2023-03-03 北京美康基免生物科技有限公司 一种抗psma单链抗体及与其相关的嵌合抗原受体和应用
WO2024196776A2 (en) * 2023-03-17 2024-09-26 Dana-Farber Cancer Institute, Inc. Developing an anti-human cd45 imaging probe for noninvasive detection of human immune cells
AU2024346987A1 (en) 2023-09-19 2026-04-02 Telix Targeting Technologies, Inc. Antigen binding constructs
US20250332281A2 (en) 2023-12-15 2025-10-30 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof

Family Cites Families (383)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4709015A (en) 1979-12-04 1987-11-24 Ortho Pharmaceutical Corporation Monoclonal antibody to human suppressor T cells
US5292668A (en) 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
CA1335879C (en) 1987-07-27 1995-06-13 Bruce Andrew Cornell Receptor membranes
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US4943525A (en) 1987-11-02 1990-07-24 Bioventures, Inc. Simultaneous immunoassay for the determination of antigens and antibodies
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US4892824A (en) 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5980896A (en) 1989-06-30 1999-11-09 Bristol-Myers Squibb Company Antibodies reactive with human carcinomas
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4134982A1 (de) 1991-10-23 1993-04-29 Kernforschungsz Karlsruhe Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE4140142A1 (de) 1991-12-05 1993-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim, De Multivalentes dextranreagenz zum einsatz in praezipitationstests
EP0618970A1 (en) 1991-12-10 1994-10-12 Dana Farber Cancer Institute Reactive neutralizing human anti-gp120 recombinant antibody, dna coding the same and use thereof
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
WO1994008038A1 (en) 1992-10-02 1994-04-14 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
DE69334071T2 (de) 1992-11-05 2007-10-25 Sloan-Kettering Institute For Cancer Research Prostata-spezifisches membranantigen
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5376249A (en) 1992-11-25 1994-12-27 Perseptive Biosystems, Inc. Analysis utilizing isoelectric focusing
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
ATE187494T1 (de) 1992-12-11 1999-12-15 Dow Chemical Co Multivalente einkettige antikörper
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5705614A (en) 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6001581A (en) 1993-06-04 1999-12-14 Sibia Neurosciences, Inc. Cation-based bioassay using human metabotropic glutamate receptors
US5521297A (en) 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
US5912122A (en) 1993-06-04 1999-06-15 Sibia Neurosciences, Inc. Nucleic acids encoding and method for detecting nucleic acid encoding human metabotropic glutamate receptor subtype mGluR6
US5869049A (en) 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
AU695641B2 (en) 1993-09-20 1998-08-20 Novartis Ag Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds
US5935818A (en) 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
WO1995022609A2 (en) 1994-02-21 1995-08-24 The Wellcome Foundation Limited Human glutamate receptor proteins
DE4421391C1 (de) 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5688690A (en) 1994-09-16 1997-11-18 The Wistar Institute Of Anatomy And Biology Human cytotoxic lymphocyte signal transduction surface protein (P38) and monoclonal antibodies thereto
AU717937B2 (en) 1995-02-24 2000-04-06 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9504344D0 (en) 1995-03-03 1995-04-19 Unilever Plc Antibody fragment production
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US5830478A (en) 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
EP0856054B1 (en) 1995-10-19 2004-04-28 Bristol-Myers Squibb Company Monoclonal antibody br110 and uses thereof
US6084084A (en) 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
US20040253246A1 (en) 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
US6384205B1 (en) 1996-03-12 2002-05-07 Eli Lilly And Company Metabotropic glutamate receptor 4 nucleic acid
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
EP0914155B1 (en) 1996-03-25 2006-02-22 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
JP2000503773A (ja) 1996-05-23 2000-03-28 ユニリーバー・ナームローゼ・ベンノートシヤープ 特異的結合アッセイの改良
US6221609B1 (en) 1996-07-03 2001-04-24 Eli Lilly And Company Isolate nucleic acid encoding human MGLUR8
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
DK0932417T3 (da) 1996-10-17 2003-04-14 Immunomedics Inc Non-antigent toxinkonjugat og fusionsprotein af internaliserende receptorsystem
CA2276462C (en) 1996-12-31 2007-06-12 High Throughput Genomics, Inc. Multiplexed molecular analysis system apparatus and method
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
EP0977837A1 (en) 1997-04-03 2000-02-09 Universite Laval Transgenic expression in genital tract and sexual accessory glands
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6187284B1 (en) 1997-09-03 2001-02-13 Immunomedics, Inc. Fluorination of proteins and peptides for F-18 positron emission tomography
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US6030792A (en) 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6200765B1 (en) 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
US6071490A (en) 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
ATE473242T1 (de) 1998-05-20 2010-07-15 Immunomedics Inc Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6103524A (en) 1998-07-30 2000-08-15 Eli Lilly And Company Metabotropic glutamate receptor protein and nucleic acid
WO2000014234A1 (en) 1998-09-08 2000-03-16 Urocor, Inc. Prostate specific promoter and regulation of gene expression
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
JP2002538767A (ja) 1998-09-29 2002-11-19 ザ ユーエイビー リサーチ ファンデイション 樹状細胞およびｂ細胞の遺伝子組換えによる免疫調節
US6835866B1 (en) 1998-12-10 2004-12-28 Board Of Regents, The University Of Texas Systems Compositions and methods of modulating cholesterol metabolism
CA2370237A1 (en) 1999-04-13 2000-10-19 Northwest Biotherapeutics, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
WO2001009303A2 (en) 1999-07-30 2001-02-08 Vical Inc. Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
KR100510795B1 (en) 1999-08-31 2005-08-30 Compositions and Methods for the Treatment of Tumor
US20040209314A1 (en) 1999-09-06 2004-10-21 Institut National De La Sante Et De La Recherche Medicale France Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA
US6342587B1 (en) 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
US20040038339A1 (en) 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US6608176B2 (en) 2000-03-31 2003-08-19 University Of Miami Taste receptor for umami (monosodium glutamate) taste
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
WO2001074905A1 (en) 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
DK1276896T3 (da) 2000-04-28 2010-10-18 Mannkind Corp Epitop-synkronisering i antigen-præsenterende celler
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US8106174B2 (en) 2000-05-08 2012-01-31 Monsanto Technology Llc Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US6375991B1 (en) 2000-09-08 2002-04-23 Albemarle Corporation Production of concentrated biocidal solutions
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20030235833A1 (en) 2001-06-18 2003-12-25 National Institute Of Advanced Industrial Science And Technology Guanosine triphosphate-binding protein coupled receptors
US20030143668A1 (en) 2001-06-18 2003-07-31 National Institute Of Advanced Industrial Guanosine triphosphate-binding protein coupled receptors
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CN1142183C (zh) 2001-08-23 2004-03-17 北京大学人民医院 抗独特型微抗体及其制备方法和应用
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1427377A4 (en) 2001-09-20 2006-04-12 Cornell Res Foundation Inc METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISORDERS USING SPECIFIC BINDING AGENTS FOR A PROSTATE-SPECIFIC MEMBRANE ANTIGEN
WO2003035873A1 (en) 2001-10-23 2003-05-01 Ajinomoto Co, Inc Novel glutamic acid receptor and utilization thereof
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
CN101024842A (zh) 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
US20040018519A1 (en) 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
US7452539B2 (en) 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
EP1499353A4 (en) 2002-04-15 2006-04-05 Human Genome Sciences Inc SPECIFIC TO TL5 BINDING ANTIBODIES
WO2003089930A1 (en) 2002-04-22 2003-10-30 Georgetown University Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
AU2013203285B2 (en) * 2002-05-22 2015-04-23 Novartis Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7993626B2 (en) 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7563433B2 (en) 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7597876B2 (en) 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
EP2365004B1 (en) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
EP1567555A4 (en) 2002-11-27 2006-06-21 Biogen Idec Inc HUMANIZED ANTIBODIES AGAINST CHEMOTOXIC MONOCYTE PROTEINS
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1583821A4 (en) 2003-01-15 2007-07-18 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING GENES 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
MXPA05008222A (es) 2003-01-31 2005-10-05 Immunomedics Inc Metodos y composiciones para administrar agentes terapeuticos y de diagnostico.
US20050042217A1 (en) 2003-03-19 2005-02-24 Yan Qi Specific inhibition of allorejection
US20050026178A1 (en) 2003-03-28 2005-02-03 Marit Nilsen-Hamilton Allosteric probes and methods
GB0308988D0 (en) 2003-04-17 2003-05-28 Univ Singapore Molecule
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
CA2526274C (en) 2003-05-30 2015-12-01 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
US7541442B2 (en) 2003-05-30 2009-06-02 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
RU2005137325A (ru) 2003-05-31 2006-09-10 Микромет Аг (De) Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
DK1629011T3 (da) 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
JP2006526414A (ja) 2003-06-02 2006-11-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 脱免疫化抗ｃｄ３抗体
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
DK3095793T3 (da) 2003-07-28 2020-05-25 Genentech Inc Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US7569389B2 (en) 2004-09-30 2009-08-04 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics
US20060150283A1 (en) 2004-02-13 2006-07-06 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
US20120159672A1 (en) 2004-02-06 2012-06-21 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
US20050176028A1 (en) 2003-10-16 2005-08-11 Robert Hofmeister Deimmunized binding molecules to CD3
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
ITPD20030264A1 (it) 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2553261C (en) 2004-01-16 2014-03-18 Stefan Barth Immunokinases
US20060235212A1 (en) 2004-12-22 2006-10-19 Nickolai Alexandrov Nucleic acid sequences encoding zinc finger proteins
EP1716178B1 (en) 2004-02-16 2010-08-11 Micromet AG Less immunogenic binding molecules
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7273608B2 (en) 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
WO2005101017A1 (en) 2004-04-07 2005-10-27 Genentech, Inc. Mass spectrometry of antibody conjugates
AU2004319915B9 (en) 2004-04-22 2011-12-22 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US20080227736A1 (en) 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
US20050281740A1 (en) 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US20060159689A1 (en) 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005263555B2 (en) 2004-07-16 2011-01-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006050058A2 (en) 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
US20080193376A1 (en) 2004-10-28 2008-08-14 The General Hospital Corporation Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7335760B2 (en) 2004-12-22 2008-02-26 Ceres, Inc. Nucleic acid sequences encoding zinc finger proteins
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
AU2006210724A1 (en) 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
CA2600929A1 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
CN1854295A (zh) 2005-04-25 2006-11-01 上海新生源医药研究有限公司 卵巢癌抗独特型微抗体的生产方法
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
JP2007014267A (ja) 2005-07-07 2007-01-25 Toyama Univ Ｂ型肝炎ウイルスのＨＢｓ抗原に対するモノクローナル抗体、それに関連する遺伝子およびペプチド、並びにＢ型肝炎ウイルスの検定方法、Ｂ型肝炎の診断方法、治療方法
WO2007009064A2 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1942944A2 (en) 2005-10-31 2008-07-16 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
US7846439B2 (en) 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
US20070212331A1 (en) 2006-03-07 2007-09-13 Baldassare Joseph J Methods and compositions for selectively killing cells
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2007109749A2 (en) 2006-03-21 2007-09-27 Wyeth Methods for preventing and treating amyloidogenic diseases
EP2010216A4 (en) 2006-03-24 2010-06-09 Donald L Morton MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US7566276B2 (en) 2006-04-14 2009-07-28 Dogleg Right Corporation Multi-piece putter head having an insert
WO2007137117A2 (en) 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
JP2010507645A (ja) 2006-10-25 2010-03-11 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 前立腺癌を検出するための造影剤
WO2008079302A2 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8709382B2 (en) 2007-01-11 2014-04-29 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
CN101568352B (zh) 2007-01-11 2013-08-21 免疫医学股份有限公司 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
US20160045626A1 (en) 2007-01-11 2016-02-18 Immunomedics, Inc. Methods and Compositions for Improved Labeling of Targeting Peptides
US20150086482A1 (en) 2007-01-11 2015-03-26 Immunomedics, Inc. Dye Conjugated Peptides for Fluorescent Imaging
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
EP2187971A2 (en) 2007-08-01 2010-05-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services A fold-back diabody diphtheria toxin immunotoxin and methods of use
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
AU2008311869B2 (en) 2007-10-17 2013-11-21 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for crystallizing G protein-coupled receptors
AU2008312444B2 (en) 2007-10-18 2014-02-06 Bavarian Nordic A/S Use of MVA to treat prostate cancer
CA2703140A1 (en) 2007-10-25 2009-04-30 Viventia Biotech Inc. Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof
WO2009070636A2 (en) 2007-11-27 2009-06-04 Stanford University Engineered cells, imaging reporter gene/probe systems, and methods of imaging
US9107858B2 (en) 2007-12-05 2015-08-18 Wisconsin Alumni Research Foundation Dendritic cell targeting compositions and uses thereof
US8603474B2 (en) 2008-01-29 2013-12-10 Ludwig Institute For Cancer Research, Ltd. Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
EP2240495B1 (en) 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
US8043830B2 (en) 2008-02-01 2011-10-25 The Regents Of The University Of California Biotin-ligase system for secretion of biotinylated protein
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
TW200947474A (en) 2008-05-05 2009-11-16 Ren-Huan Pan Manufacturing equipment and method of quadratic arc alignment dua-turret formation center, and miniature milliohm current sensors manufactured thereof
WO2009140242A1 (en) 2008-05-13 2009-11-19 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
WO2010000796A1 (en) 2008-07-02 2010-01-07 Assistance Publique - Hôpitaux De Paris A method for predicting clinical outcome of patients with non-small cell lung carcinoma
JP2011526792A (ja) 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US20100069616A1 (en) 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
JP5309775B2 (ja) 2008-08-07 2013-10-09 セイコーエプソン株式会社 放電灯の駆動装置および駆動方法、光源装置並びに画像表示装置
EA201170357A1 (ru) 2008-08-20 2012-05-30 Сентокор Орто Байотек Инк. Инженерные антитела к il-13: композиции, способы и применение
RU2509968C2 (ru) 2008-09-08 2014-03-20 Конокофиллипс Компани Система для отделения неконденсируемого компонента на установке для сжижения природного газа
EP2334642B1 (en) 2008-09-16 2014-01-01 The Regents Of The University Of California Simplified one-pot synthesis of [18f]sfb for radiolabeling
WO2010037397A1 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
NO2344540T3 (https=) 2008-10-02 2018-04-28
AU2009303318B2 (en) 2008-10-10 2016-06-30 Aptevo Research And Development Llc TCR complex immunotherapeutics
US20110207155A1 (en) 2008-10-13 2011-08-25 Xeptagen Spa Method for the preparation of immunoconjugates and use thereof
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2010057047A1 (en) 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
DE112009001871B4 (de) 2008-12-25 2014-08-21 Tokai Rubber Industries, Ltd. Vibrationsdämpfungsvorrichtung vom fluidgefüllten Typ
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
EP2391652A4 (en) 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
US20120004289A1 (en) 2009-03-06 2012-01-05 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
EP2419120A4 (en) 2009-04-08 2016-01-06 Univ California HUMAN PROTEIN CONCERNS WITH CONTROLLED SERUM PHARMACOKINETICS
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
SG176202A1 (en) 2009-05-28 2011-12-29 Glaxo Group Ltd Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
BRPI1016061A2 (pt) 2009-05-28 2016-09-13 Glaxo Group Ltd "proteína de ligação de antígeno, célula hospedeira transfectada ou transformada recombinante, composição farmacêutica, método de tratamento de um paciente humano, uso de uma proteína de ligação de antígeno, método para a redução da agregação de um domínio variável simples de imunoglobulina, vk dab humano derivado de uma estrutura da linha germinativa, e, domínio variável simples de imunoglobulina."
US9290577B2 (en) 2009-07-03 2016-03-22 Avipep Pty Limited Immuno-conjugates and methods for producing them
WO2011003171A1 (en) 2009-07-08 2011-01-13 Smart Technologies Ulc Three-dimensional widget manipulation on a multi-touch panel
TWM383852U (en) 2009-07-13 2010-07-01 Speedtech Corp An improvement of the universal serial bus connector
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JPWO2011043061A1 (ja) 2009-10-05 2013-03-04 キヤノン株式会社 光音響イメージング用造影剤、及び、それを用いた光音響イメージング方法
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
WO2011067202A1 (en) 2009-12-02 2011-06-09 Unilever Nv Improved method for screening a potential modulator compound of a taste receptor
AU2010326004B2 (en) 2009-12-04 2016-04-21 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
JP2013514788A (ja) 2009-12-23 2013-05-02 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法２
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
EP2531853B1 (en) 2010-02-04 2015-06-10 Agency For Science, Technology And Research Use of novel markers of pluripotent stem cells
US20130137975A1 (en) 2010-02-09 2013-05-30 OSI Pharmaceuticals, LLC Pet imaging
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9812638B2 (en) 2010-03-19 2017-11-07 Globalfoundries Inc. Backend of line (BEOL) compatible high current density access device for high density arrays of electronic components
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
EP2611826B1 (en) 2010-08-30 2016-09-21 Confometrx, Inc. Method and composition for crystallizing a family c gpcr
WO2012057697A1 (en) 2010-10-28 2012-05-03 Modmab Limited Uk Filial New diagnostic and therapeutic target
US20120144110A1 (en) 2010-12-02 2012-06-07 Lsi Corporation Methods and structure for storage migration using storage array managed server agents
EP2471543A1 (en) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
EP2476754A1 (en) 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CA2880791A1 (en) 2011-08-03 2013-02-07 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2013130177A1 (en) 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
WO2013188693A1 (en) 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014025828A1 (en) 2012-08-06 2014-02-13 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
HK1220465A1 (zh) * 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
US9168300B2 (en) * 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
CN113248613B (zh) 2014-01-15 2024-08-23 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
AU2015259533B2 (en) 2014-05-10 2019-11-28 Vivasor, Inc. Chemically-locked bispecific antibodies
EP2966085A1 (en) 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
CN121159719A (zh) 2015-04-17 2025-12-19 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3291836A4 (en) 2015-05-06 2018-11-14 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
US11820807B2 (en) * 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
US20160362473A1 (en) * 2015-06-12 2016-12-15 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
WO2017007807A1 (en) 2015-07-07 2017-01-12 Immunomedics, Inc. IMPROVED METHODS OF IMAGING WITH Ga-68 LABELED MOLECULES
US11254744B2 (en) * 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
CN108513576A (zh) 2015-09-14 2018-09-07 高山免疫科学股份有限公司 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
KR102693802B1 (ko) 2016-02-15 2024-08-08 프라운호퍼-게젤샤프트 츄어 푀르더룽 데어 안게반텐 포르슝에.파우. 변형된 이식편의 사전 사용에 의한 이식편 거부의 방지
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
EP3266465A1 (en) 2016-07-06 2018-01-10 Julius-Maximilians-Universität Würzburg Immune complexes
WO2018053328A1 (en) 2016-09-16 2018-03-22 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2018187215A1 (en) 2017-04-03 2018-10-11 Merrimack Pharmaceuticals, Inc. Bispecific 4-1bb agonist molecules
AU2018265261B2 (en) 2017-05-10 2025-05-22 Inovio Pharmaceuticals, Inc. Optimized nucleic acid antibody constructs
KR20200014379A (ko) * 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
US11597764B2 (en) 2017-06-15 2023-03-07 Memorial Sloan Kettering Cancer Center Anti-L1-CAM antibodies and uses thereof
WO2019012147A1 (en) 2017-07-13 2019-01-17 Institut Gustave-Roussy RADIOMY-BASED IMAGING TOOL FOR MONITORING INFILTRATION AND TUMOR LYMPHOCYTE AND RESULTS IN CANCER PATIENTS TREATED WITH ANTI-PD-1 / PD-L1 AGENTS
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
MX2020000903A (es) 2017-08-11 2020-07-22 Genentech Inc Anticuerpos anti-cd8 y usos de los mismos.
US11672877B2 (en) 2017-08-23 2023-06-13 Wayne State University In vivo immunoimaging of interferon-gamma
AU2018338322B2 (en) 2017-09-23 2025-07-17 Memorial Sloan Kettering Cancer Center A33 antibody compositions and methods of using the same in radioimmunotherapy
CA3177757A1 (en) 2018-02-16 2019-08-22 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
CN119930831A (zh) 2018-03-14 2025-05-06 纪念斯隆凯特琳癌症中心 抗聚唾液酸抗体及其用途
WO2019236684A1 (en) 2018-06-08 2019-12-12 Imaginab, Inc. Antigen binding constructs to cd4
KR20210087938A (ko) * 2018-09-28 2021-07-13 이미지냅 인코포레이티드 Cd8 이미징 구조체 및 이의 사용 방법
EP4288455A1 (en) * 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same

Also Published As

Publication number Publication date
AU2023200616B2 (en) 2024-10-31
NZ739721A (en) 2019-09-27
CN115960230A (zh) 2023-04-14
JP2022095755A (ja) 2022-06-28
JP2020100668A (ja) 2020-07-02
KR20180050321A (ko) 2018-05-14
AU2016304764C1 (en) 2023-06-01
SG10201913625XA (en) 2020-03-30
KR20250008141A (ko) 2025-01-14
CN108136012B (zh) 2022-10-04
CN108136012A (zh) 2018-06-08
RU2765242C2 (ru) 2022-01-27
RU2018105374A (ru) 2019-09-09
JP7828375B2 (ja) 2026-03-11
AU2025200544A1 (en) 2025-02-20
JP2024069225A (ja) 2024-05-21
JP7097923B2 (ja) 2022-07-08
EP3331564B1 (en) 2025-01-08
EP3331564A4 (en) 2019-05-22
RU2018105374A3 (https=) 2019-09-09
KR102749049B1 (ko) 2025-01-02
AU2023200616A1 (en) 2023-03-09
HK1255107A1 (zh) 2019-08-02
MX2022014463A (es) 2022-12-08
BR112018002451A2 (en) 2018-09-18
JP2018529758A (ja) 2018-10-11
JP7026613B2 (ja) 2022-02-28
EP3331564A1 (en) 2018-06-13
US20170051044A1 (en) 2017-02-23
ES3020458T3 (en) 2025-05-22
JP7487250B2 (ja) 2024-05-20
AU2016304764A1 (en) 2018-03-01
CA2994951A1 (en) 2017-02-16
AU2016304764B2 (en) 2022-12-08
EP4137158A1 (en) 2023-02-22
ZA201801391B (en) 2018-12-19
US11254744B2 (en) 2022-02-22
US20220089730A1 (en) 2022-03-24
WO2017027325A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
MX2018001566A (es) Construcciones de union a antigeno para moleculas diana.
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
CY1124472T1 (el) Κατασκευασματα διειδικων αντισωματων που δεσμευουν dll3 και cd3
MX2020001879A (es) Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
MX2024001803A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
MX2018013548A (es) Proteinas de union biespecificas y usos de las mismas.
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2018001326A1 (es) Proteínas de unión a ctla4.
PE20181013A1 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
CU20170169A7 (es) Anticuerpos de factor xi
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12017500890A1 (en) Antibody drug conjugates
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
UA117364C2 (uk) Похідні аматоксину
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
MX384419B (es) Constructos de anticuerpos para cdh19 y cd3
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
KR20220016865A9 (ko) 항원 결합 분자, 약학 조성물, 및 방법
AR113343A1 (es) ANTICUERPO MONOCLONAL ANTI-IL-5Ra